Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers
Summary: Lakewood-Amedex reported encouraging preclinical data showing minimal resistance development to its novel Bisphosphocin antimicrobial compounds in models relevant to infected diabetic foot ulcers (DFU). With resistant pathogens complicating 15–20% of DFU cases and a massive economic burden, this candidate offers a potential new option with a low propensity for resistance — an important advantage over traditional antibiotics.
Key Highlights:
- Low resistance emergence in antimicrobial testing against DFU-relevant pathogens
- Addresses critical need in infected DFUs where resistance is common
- Supports further development of novel bisphosphocin technology
Keywords: Bisphosphocin DFU, infected diabetic foot ulcer, antimicrobial resistance wound